Introduction

TELMIARK-XL TRIO is a triple-combination antihypertensive formulation developed by Rednirus Cardiocare, a leading name in cardiac specialty pharma solutions. This advanced once-daily tablet combines three potent agents—Metoprolol Succinate ER, Telmisartan, and Cilnidipine—to deliver comprehensive, synergistic blood pressure control. It not only controls systolic and diastolic pressure but also offers protection against target organ damage, cardiovascular risk, and variability in BP levels throughout the day.

Ideal for patients who require intensive and sustained control of hypertension, TELMIARK-XL TRIO offers convenience, compliance, and superior clinical outcomes.

Composition Overview

1. Metoprolol Succinate 50mg (Extended Release)
    
   • Class: Cardio-selective β1-blocker
      
   • Action: Reduces heart rate, myocardial contractility, and cardiac output
      
   • Benefit: Prevents angina, arrhythmias, and cardiac remodeling
      
2. Telmisartan 40mg
    
   • Class: Angiotensin II receptor blocker (ARB)
      
   • Action: Blocks vasoconstrictive effects of angiotensin II
      
   • Benefit: Vasodilation, renal protection, long-acting BP control
      
3. Cilnidipine 10mg
    
   • Class: Dual L/N-type calcium channel blocker
      
   • Action: Vasodilator that relaxes both peripheral blood vessels and sympathetic nerves
      
   • Benefit: Lowers blood pressure, reduces sympathetic tone, offers reno- and cardio-protection
      

Mechanism of Action: How TELMIARK-XL TRIO Works

This triple-action formula provides multi-modal antihypertensive therapy:

• Metoprolol Succinate (β-blocker):
  Inhibits β1-adrenergic receptors → ↓ heart rate and cardiac output → ↓ BP and myocardial oxygen demand.
   
• Telmisartan (ARB):
  Blocks angiotensin II at AT1 receptors → prevents vasoconstriction & aldosterone release → ↑ vasodilation → ↓ BP and improved renal perfusion.
   
• Cilnidipine (CCB):
  Inhibits L-type calcium channels in vessels → vasodilation.
  Inhibits N-type channels in sympathetic nerves → ↓ norepinephrine → ↓ BP surges and heart stress.
   

Together, these three drugs provide 24-hour control of hypertension, reduce cardiovascular risk, and offer neurohormonal and vascular protection.

Clinical Indications

TELMIARK-XL TRIO is indicated in:

• Stage II & Resistant Hypertension
   
• Essential Hypertension not controlled by dual therapy
   
• Hypertension with left ventricular hypertrophy (LVH)
   
• Cardiac hypertrophy, ischemia, or high pulse pressure
   
• Diabetic nephropathy & chronic kidney disease (CKD) with hypertension
   
• Hypertensive heart disease with increased sympathetic tone
   

Advantages of TELMIARK-XL TRIO

• Triple Mechanism: Combines β-blockade, RAAS inhibition, and calcium channel blocking in one pill
• Target Organ Protection: Cardioprotective, nephroprotective, and neuroprotective
•  Once-Daily Convenience: Improves patient compliance & simplifies regimen
• Reduced Pill Burden: Ideal for long-term hypertensive patients with co-morbidities
•  Minimal Side Effects: Well-tolerated with low incidence of peripheral edema (thanks to cilnidipine)
•  Enhanced 24-Hour Control: Sustained blood pressure control including early morning surge

Dosage & Administration

Recommended Dosage:

• One tablet daily, preferably in the morning
   
• Should be taken with water, with or without food
   

Titration:

• Dose may be adjusted based on patient response and BP goals
   
• Periodic renal and electrolyte monitoring advised in patients with CKD
   

Contraindications

• Cardiogenic shock or acute heart failure
   
• Severe bradycardia or AV block (Metoprolol sensitivity)
   
• Pregnancy & lactation (Telmisartan should be avoided)
   
• Known hypersensitivity to any component
   
• Severe hepatic impairment
   

Side Effects

Most patients tolerate TELMIARK-XL TRIO well. Possible mild side effects may include:

• Dizziness or fatigue (Metoprolol)
   
• Mild bradycardia
   
• Swelling of ankles (less common with Cilnidipine than with amlodipine)
   
• Headache or flushing
   
• Dry mouth or abdominal discomfort
   
• Electrolyte imbalance (rare)
   

Prompt consultation is advised if persistent dizziness, palpitations, or unusual swelling occurs.

Drug Interactions

• NSAIDs: May reduce the antihypertensive effect
   
• Other antihypertensives: Additive effect; monitor closely
   
• Antidiabetics: Beta-blockers may mask hypoglycemia symptoms
   
• Lithium or potassium-sparing diuretics: Monitor serum potassium and renal function

Patient Advice

• Do not discontinue the medicine abruptly
   
• Maintain regular check-ups for BP and ECG
   
• Monitor blood sugar if diabetic
   
• Avoid alcohol and smoking
   
• Maintain a low-sodium diet and engage in physical activity

Why Choose Rednirus Cardiocare for TELMIARK-XL TRIO?

Rednirus Cardiocare is a dedicated cardiac-specialty division of Rednirus Healthcare, committed to improving cardiovascular outcomes in India through evidence-based formulations, innovative fixed-dose combinations, and affordable cardiac therapy options.

Reasons to trust Rednirus Cardiocare:

•  WHO-GMP certified manufacturing
   
•  Clinically balanced combinations with real-world benefits
   
•  Attractive packaging, long shelf life, and quality assurance
   
•  Backed by strong medical literature and promotional support
   
•  Franchise-friendly with monopoly PCD opportunities
   
•  Trusted by cardiologists, general practitioners & internists

 Business Scope – PCD Franchise Opportunity

TELMIARK-XL TRIO is not only a breakthrough in hypertension therapy but also a strong business product for PCD pharma franchisees under Rednirus Cardiocare.

Why this product has high market potential:

• Rising incidence of hypertension & cardiac disorders in India
   
• Growing demand for fixed-dose combinations for improved compliance
   
• Acceptance of cilnidipine over older CCBs due to its unique dual action
   
• Favorable safety and tolerability profile in elderly and diabetic populations
   
• Excellent doctor recall with strong brand positioning
   

PCD Franchise Support Includes:

• Monopoly rights

• Visual aids & promotional kits

• Free samples & product cards

• Timely delivery & logistics support

• Digital tools for MR promotion

Conclusion

TELMIARK-XL TRIO is a powerful and well-balanced fixed-dose combination that provides holistic control of hypertension and its complications. It is thoughtfully designed by Rednirus Cardiocare to serve patients who need multi-modal therapy for cardiovascular risk management.

With its patient-centric profile, doctor-trusted composition, and strong market potential, TELMIARK-XL TRIO is an ideal addition to your antihypertensive portfolio—whether you're a healthcare provider or a PCD entrepreneur.

.